| Literature DB >> 32148542 |
Guifeng Qian1,2, Jingchun Zeng3, Liming Lu4, Wenya Pei5, Kun Liu6, Zhenke Luo6, Yalin She6, Pande Zhang2, Guohua Lin3.
Abstract
OBJECTIVE: To explore the methods for improving the reporting quality of randomised controlled trials (RCTs) on acupuncture through evaluating the reporting quality in RCTs of acupuncture for acute herpes zoster by the CONSORT statement and STRICTA guidelines.Entities:
Year: 2020 PMID: 32148542 PMCID: PMC7049440 DOI: 10.1155/2020/4308380
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Reporting quality using items from the CONSORT statement (n = 40 studies).
| Reporting quality using items from the CONSORT statement ( | No. of positive trials | % | 95% CI | Cohen's Kappa | 95% CI | |
|---|---|---|---|---|---|---|
| “Randomised” in the title or abstract | “Randomised” in the title or abstract | 35 | 88 | 77 to 99 | 0.77 | 0.63 to 0.91 |
| Background | Adequate description of the scientific background and explanation of rationale | 36 | 90 | 80 to 99 | 0.84 | 0.72 to 0.96 |
| Trial design | Description of trial design (such as parallel and factorial) including the allocation ratio | 7 | 18 | 5 to 31 | 0.81 | 0.68 to 0.94 |
| Participants | Description of the eligibility criteria for participants | 21 | 53 | 37 to 69 | 0.70 | 0.55 to 0.85 |
| Interventions | Details of the interventions intended for each group(refer | — | — | — | — | — |
| Outcomes | Definition of primary (and secondary when appropriate) outcome measures | 31 | 78 | 64 to 92 | 0.59 | 0.43 to 0.75 |
| Sample size | Description of sample size calculation | 2 | 5 | 0 to 12 | 1 | — |
| Randomisation | (a) Method used to generate the random allocation sequence | 13 | 33 | 18 to 48 | 0.70 | 0.55 to 0.85 |
| (b) Type of randomisation details of any restriction | 0 | 0 | — | — | — | |
| Allocation concealment | Description of the method used to implement the random allocation sequence assuring the concealment until interventions were assigned | 0 | 0 | — | — | — |
| Implementation | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 3 | 8 | 0 to 17 | 0.36 | 0.20 to 0.51 |
| Blinding | If done, who was blinded after assignment to interventions | |||||
| (a) Participants | 0 | |||||
| (b) Care providers | 0 | |||||
| (c) Outcome assessors | 1 | 3 | 0 to 9 | 1 | — | |
| Statistical methods | Description of the statistical methods used to compare groups for primary outcomes, subgroup analyses, or adjusted analyses | 34 | 85 | 73 to 97 | 0.47 | 0.31 to 0.63 |
| Flow chart | Details on the flow of participants through each stage of the trials | 2 | 5 | 0 to 12 | 1 | — |
| Recruitment | Dates defining the periods of recruitment and follow-up | 27 | 68 | 53 to 83 | 0.58 | 0.41 to 0.74 |
| Baseline data | An outline of baseline demographic and clinical characteristics of each group | 29 | 73 | 58 to 88 | 0.78 | 0.64 to 0.92 |
| Intent-to-treat analysis | Number of participants in each group included in each analysis and whether it was done by “intention-to-treat” | 0 | 0 | — | 1 | — |
| Outcomes and estimation | For each primary and secondary outcome, summary of results for each group was given as well as the estimated effect size and its precision (e.g., 95% CI) | 40 | 100 | — | 1 | — |
| Ancillary analyses | Clear statement of whether subgroup/adjusted analyses were prespecified or exploratory | 0 | 0 | — | 1 | — |
| Adverse events | Description of all important adverse events in each group | 7 | 18 | 5 to 30 | 0.92 | 0.83 to 1 |
| Clinical trials register | Whether to conduct clinical trial registration | 1 | 3 | 0 to 9 | 1 | — |
| Funding | Fund support | 8 | 20 | 7 to 33 | 0.92 | 0.81 to 1 |
Reporting quality of details of needling from STRICTA (n = 40).
| Details of needling | No. of positive trials | % | 95% CI | Cohen's Kappa | 95% CI | |
|---|---|---|---|---|---|---|
| Acupuncture rational | Reasoning for treatment provided | 38 | 95 | 87 to 100 | 0.66 | 0.50 to 0.81 |
|
| ||||||
| Points used | Names or location of points used | 38 | 95 | 87 to 100 | 1 | — |
| Numbers of needles inserted | Number of needle insertions per session | 17 | 43 | 27 to 59 | 0.85 | 0.73 to 0.97 |
| Depth of insertion | Depth of insertion | 18 | 45 | 29 to 61 | 0.56 | 0.40 to 0.72 |
| Responses elicited | Responses sought (e.g., | 19 | 48 | 32 to 64 | 0.37 | 0.21 to 0.53 |
| Needle stimulation | Needle stimulation (e.g., manual or electrical) | 34 | 85 | 73 to 97 | 0.46 | 0.30 to 0.62 |
| Needle retention time | Needle retention time per session | 38 | 95 | 88 to 100 | 1 | — |
| Needle type | Needle type (diameter, length and manufacturer or material) | 27 | 68 | 53 to 83 | 0.38 | 0.22 to 0.54 |
|
| ||||||
| Treatment frequency | Treatment frequency | 35 | 88 | 77 to 98 | 0.86 | 0.75 to 0.97 |
| Course of treatment | Treatment course | 35 | 88 | 77 to 98 | 0.77 | 0.63 to 0.90 |
| Practitioner background | Description of acupuncturists | 1 | 3 | 0 to 9 | 1 | — |
| Control intervention | Precise description of the control or comparator. | 40 | 100 | — | 1 | — |
Figure 1Flow chart of study selection of RCTs of acupuncture for acute HZ.
Figure 2Number of RCTs of acupuncture for acute HZ published per year.